Global biotech leader in plasma-derived therapies and vaccines
CSL Seqirus Signs Long-Term Agreement with The Pan-American Health Organization (PAHO) to Advance Regional Influenza Protection in the Region of the Americas
CSL Seqirus entered into a long-term agreement with the Pan-American Health Organization (PAHO) to enhance influenza protection across the Americas.
Lilly and CSL Partner on Clazakizumab Antibody Development
CSL and Eli Lilly have entered into a strategic licensing agreement for the development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody.
CSL announces expansion of Illinois plasma therapy manufacturing facility
CSL announced a $1.5 billion investment to expand its plasma therapy manufacturing facility in Kankakee, Illinois, which is expected to create at least 300 new jobs.
当该公司有新信号时,立即收到通知。